Resource Summary Report

Generated by FDI Lab - SciCrunch.org on Apr 17, 2025

InVivoPlus anti-mouse CD40

RRID:AB_1107647
Type: Antibody

Proper Citation

(Bio X Cell Cat# BE0016-2, RRID:AB_1107647)

Antibody Information

URL: http://antibodyregistry.org/AB_1107647

Proper Citation: (Bio X Cell Cat# BE0016-2, RRID:AB_1107647)

Target Antigen: CD40

Host Organism: rat

Clonality: monoclonal

Comments: Applications: in vivo CD40 activation, in vitro B cell stimulation/activation Consolidation on 12/2021: AB_1107647, AB_2894787.

Antibody Name: InVivoPlus anti-mouse CD40

Description: This monoclonal targets CD40

Target Organism: mouse

Clone ID: clone FGK4.5/FGK45

Antibody ID: AB_1107647

Vendor: Bio X Cell

Catalog Number: BE0016-2

Alternative Catalog Numbers: BP0016-2-50MG, BE0016-2-100MG, BP0016-2-5MG, BE0016-2-50MG, BP0016-2-25MG, BE0016-2-25MG, BP0016-2-100MG, BE0016-2-5MG, BE0016-2-1MG

Record Creation Time: 20231110T031700+0000

Record Last Update: 20240725T025332+0000

Ratings and Alerts

No rating or validation information has been found for InVivoPlus anti-mouse CD40.

No alerts have been found for InVivoPlus anti-mouse CD40.

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 34 mentions in open access literature.

Listed below are recent publications. The full list is available at FDI Lab - SciCrunch.org.

Norman KM, et al. (2024) Clostridioides difficile toxin B subverts germinal center and antibody recall responses by stimulating a drug-treatable CXCR4-dependent mechanism. Cell reports, 43(5), 114245.

Tamari M, et al. (2024) Sensory neurons promote immune homeostasis in the lung. Cell, 187(1), 44.

Wang H, et al. (2024) Preclinical study and phase II trial of adapting low-dose radiotherapy to immunotherapy in small cell lung cancer. Med (New York, N.Y.), 5(10), 1237.

Shapir Itai Y, et al. (2024) Bispecific dendritic-T cell engager potentiates anti-tumor immunity. Cell, 187(2), 375.

Rosenlehner T, et al. (2024) Reciprocal regulation of mTORC1 signaling and ribosomal biosynthesis determines cell cycle progression in activated T cells. Science signaling, 17(859), eadi8753.

Wattenberg MM, et al. (2023) Cancer immunotherapy via synergistic coactivation of myeloid receptors CD40 and Dectin-1. Science immunology, 8(89), eadj5097.

Pioli KT, et al. (2023) Thymus antibody-secreting cells possess an interferon gene signature and are preferentially expanded in young female mice. iScience, 26(3), 106223.

Sapoznikov A, et al. (2023) Dendritic cell ICAM-1 strengthens synapses with CD8 T cells but is not required for their early differentiation. Cell reports, 42(8), 112864.

Fike AJ, et al. (2023) STAT3 signaling in B cells controls germinal center zone organization and recycling. Cell reports, 42(5), 112512.

Kilian M, et al. (2023) MHC class II-restricted antigen presentation is required to prevent dysfunction of cytotoxic T cells by blood-borne myeloids in brain tumors. Cancer cell, 41(2), 235.

Linde IL, et al. (2023) Neutrophil-activating therapy for the treatment of cancer. Cancer cell, 41(2), 356.

Ma C, et al. (2022) Platelets control liver tumor growth through P2Y12-dependent CD40L release in NAFLD. Cancer cell, 40(9), 986.

Chang J, et al. (2022) Setd2 determines distinct properties of intestinal ILC3 subsets to regulate intestinal immunity. Cell reports, 38(11), 110530.

Herrera FG, et al. (2022) Low-Dose Radiotherapy Reverses Tumor Immune Desertification and Resistance to Immunotherapy. Cancer discovery, 12(1), 108.

Sun L, et al. (2021) Transcription factor Ascl2 promotes germinal center B cell responses by directly regulating AID transcription. Cell reports, 35(9), 109188.

Siolas D, et al. (2021) Gain-of-function p53R172H mutation drives accumulation of neutrophils in pancreatic tumors, promoting resistance to immunotherapy. Cell reports, 36(8), 109578.

Duraiswamy J, et al. (2021) Myeloid antigen-presenting cell niches sustain antitumor T cells and license PD-1 blockade via CD28 costimulation. Cancer cell, 39(12), 1623.

Blake SJ, et al. (2021) The immunotoxicity, but not anti-tumor efficacy, of anti-CD40 and anti-CD137 immunotherapies is dependent on the gut microbiota. Cell reports. Medicine, 2(12), 100464.

Monteiro de Oliveira Novaes JA, et al. (2021) Targeting of CD40 and PD-L1 Pathways Inhibits Progression of Oral Premalignant Lesions in a Carcinogen-induced Model of Oral Squamous Cell Carcinoma. Cancer prevention research (Philadelphia, Pa.), 14(3), 313.

Zhou X, et al. (2021) Stearoyl-CoA Desaturase-Mediated Monounsaturated Fatty Acid Availability Supports Humoral Immunity. Cell reports, 34(1), 108601.